Literature DB >> 2126983

Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes.

J G McKinnon1, S K Hoover, T H Inge, H D Bear.   

Abstract

Large numbers of cytotoxic T lymphocytes (CTL) could be generated from tumor-draining lymph nodes (DLN) from mice bearing PHS-5 tumor by culturing at low density with autologous tumor cell stimulators and 20 U/ml recombinant interleukin-2 (IL-2). Outgrowth of metastatic tumor cells in culture was prevented by use of this hypoxanthine/aminopterin/thymidine-sensitive mutant of P815, PHS-5. After 9 days in culture, lymphoid cells demonstrated specific cytotoxicity against autologous tumor target cells. Lymph node cells could be expanded continuously in culture with repeated tumor stimulation with up to 7500-fold increase in cell number by 6 weeks; although CTL could be activated from tumor-bearing host spleen cells in short-term culture, they showed no significant growth in long-term cultures. Phenotypically, DLN cells were a mixture of CD8+ and CD4+ cells immediately after harvest but after 2 weeks in culture they were predominantly CD8+ CD4-. CTL could be generated from tumor-bearing mice 10-14 days after i.d. tumor inoculation into the abdominal wall, but the immune response declined both in spleen and DLN by 21 days. Much greater CTL activity could be generated from axillary DLN that contained metastases than from non-draining popliteal nodes that were free of metastatic tumor cells. Some CTL activity could be generated from DLN with the addition of IL-2 alone but was further increased by the addition of more tumor cells as stimulators. When adoptively transferred to a host with 3-day P815 liver metastases, lymphocytes from DLN activated in vitro were able to reduce or eliminate metastases with very little or no IL-2 administered concomitantly. As few as 10(6) cells were therapeutically effective, and in vivo efficacy was tumor-specific, since L5178Y liver metastases were not affected.

Entities:  

Mesh:

Year:  1990        PMID: 2126983     DOI: 10.1007/bf01741722

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Accurate identification of experimental pulmonary metastases.

Authors:  H Wexler
Journal:  J Natl Cancer Inst       Date:  1966-04       Impact factor: 13.506

2.  Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases.

Authors:  C L Slingluff; T Darrow; C Vervaert; M A Quinn-Allen; H F Seigler
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

3.  Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.

Authors:  B A Ward; S Shu; T Chou; D Perry-Lalley; A E Chang
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

4.  Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.

Authors:  H D Bear
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

5.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

6.  A novel approach to the generation and identification of experimental hepatic metastases in a murine model.

Authors:  R Lafreniere; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

7.  Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.

Authors:  T Chou; A E Chang; S Y Shu
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

8.  Production of tumor-specific suppressor T cell hybridomas.

Authors:  H D Bear
Journal:  J Surg Res       Date:  1987-04       Impact factor: 2.192

9.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

10.  Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.

Authors:  F Cozzolino; M Torcia; A M Carossino; R Giordani; C Selli; G Talini; E Reali; A Novelli; V Pistoia; M Ferrarini
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  4 in total

1.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.

Authors:  N G Baldwin; C D Rice; T M Tuttle; H D Bear; J I Hirsch; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

2.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Improved survival with adjuvant immunotherapy after surgical resection in a murine model.

Authors:  L S Hamby; J W Freeman; P C McGrath
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

4.  Distribution of Mast Cells in Mediastinal Lymph Nodes from Lung Cancer Patients.

Authors:  Masaki Tomita; Yasunori Matsuzaki; Masao Edagawa; Tetsuya Shimizu; Masaki Hara; Toshio Onitsuka
Journal:  World J Surg Oncol       Date:  2003-11-18       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.